The Journal of Practical Medicine ›› 2020, Vol. 36 ›› Issue (23): 3169-3173.doi: 10.3969/j.issn.1006⁃5725.2020.23.001

• Coronavirus（COVID-19） •     Next Articles

Pharmaceutical care for COVID ⁃ 19 patients with cardiovascular disease using antiviral drugs

NI Guo⁃hua，LI Kun，YUAN Qiong#br#   

  1. Chengdu Jinjiang Sohome Comprehensive Outpatient Clinic，Chengdu 610020，China Corresponding author：YUAN Qiong E⁃mail：yuanqiong@wust.edu.cn
  • Online:2020-12-10 Published:2020-12-23
  • Contact: YUAN Qiong E⁃mail：yuanqiong@wust.edu.cn

Abstract:

Patients with cardiovascular disease （CVD） are at high risk of coronavirus disease 2019（COVID⁃19）and the mortality of COVID⁃19 patients with CVD were significantly increased.Currently，there is noevidence that any antiviral drugs were effective to severe acute respiratory syndrome coronavirus 2（SARS⁃CoV⁃2）.In August，2020，National Health Commission issued Diagnosis and Treatment Protocol for COVID⁃19（Trial Version8）and the main antiviral drugs recommended for the treatment of COVID⁃19 are IFN⁃α，Ribavirin，Chloroquinephosphate，Arbidol，Lopinavir/ritonavir（LPV/r）and so on. All of these drugs have some adverse effects on cardio⁃vascular system. The review summarizes pharmaceutical care strategy for COVID⁃19 patients with cardiovasculardisease，and aims to provide useful guidance for pharmaceutical management and treatment of COVID⁃19 patientswith CVD.

Key words: COVID?19, antiviral drug, cardiovascular disease, pharmaceutical care